Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 10/20 | 0.48 |
| ▸ | TACR1 | P25103 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191871 | 1.00 | ACACB (0.48) | ACACBTACR1KDM4EITGB3ITGA2B | |
| SCHEMBL192633 | 0.89 | TACR1 (0.48) | ACACBTACR1KDM4EITGB3ITGA2B | |
| SCHEMBL192632 | 0.89 | TACR1 (0.48) | ACACBTACR1KDM4EITGB3ITGA2B | |
| SCHEMBL13227690 | 0.87 | ITGB3 (0.41) | ACACBITGB3L3MBTL1 | |
| SCHEMBL375820 | 0.85 | CACNA1B (0.56) | ITGB3ITGA2B | |
| SCHEMBL2740259 | 0.83 | NPC1 (0.44) | ACACBLMNAALDH1A1 | |
| SCHEMBL6572925 | 0.81 | TACR1 (0.52) | TACR1ITGB3ITGA2BALDH1A1L3MBTL1 | |
| SCHEMBL8933138 | 0.81 | TACR1 (0.52) | TACR1ITGB3ITGA2BALDH1A1L3MBTL1 | |
| SCHEMBL30286967 | 0.81 | TACR1 (0.52) | TACR1ITGB3ITGA2BALDH1A1L3MBTL1 | |
| SCHEMBL12395362 | 0.78 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877366-B1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2012-01-04 | — | — | EP | disclosed |
| US-7973181-B2 | Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2011-07-05 | — | — | US | disclosed |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2009-12-03 | — | — | US | disclosed |
| EP-1877366-A1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | Chroma Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006117548-A1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | HDAC1, HDAC3, HAT1 | ACACB 523/4885TACR1 2323/4885KDM4E 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.